Sustainable Development And Responsible Business Practice Aren't Just Words At The CSL Group Of Companies

Sustainable Development And Responsible Business Practice Aren't Just Words At
                          The CSL Group Of Companies

The global biopharmaceutical's latest corporate responsibility report offers a
bird's- eye view of the company's economic, social and environmental
performance.

PR Newswire

KING OF PRUSSIA, Pa., Dec. 3, 2013

KING OF PRUSSIA, Pa., Dec. 3, 2013 /PRNewswire/ -- CSL Behring's parent
company CSL Limited (ASX:CSL) reaffirms the companies' commitment to
responsible business practice and sustainable development in its new corporate
responsibility report – Our Corporate Responsibility 2013. The report details
CSL's performance across key corporate responsibility priority areas for the
period July 1, 2012 through June 30, 2013. 

(Logo: http://photos.prnewswire.com/prnh/20100914/PH63692LOGO)

The priority areas reflect CSL Behring and CSL Limited's core values,
including research into new and improved medicines, ensuring the safety and
quality of a broad portfolio of therapies, providing a positive and healthy
work environment for employees, behaving responsibly in the global
marketplace, and providing charitable support for communities in need around
the world and minimizing the environmental impacts of its operations.

"At CSL we are passionate about innovation and providing a safe and consistent
supply of life-enhancing and lifesaving therapies around the world," said Paul
Perreault, CEO and Managing Director of CSL Limited. "We are equally diligent
about conducting our business responsibly and to actively contributing to the
well-being of our communities. I am pleased to introduce Our Corporate
Responsibility 2013 report, which illustrates our ongoing commitment with
tangible examples."

Highlights of CSL's economic, social and environmental performance include:

  oResearch and Development investment of US$427 million, with more than 35
    clinical studies in operation across our pipeline. We also achieved 17
    product registrations or indications for serious diseases.
  oEconomic contribution direct to local economies of US$4.7 billion,
    including global community investment of US$36 million to patient,
    biomedical and local communities.
  oMore than 180 regulatory audits of our manufacturing facilities with no
    impact on our product marketing licenses. Efforts to harmonize safety and
    quality processes across the organization continue.
  oGrowth of 7% in the total workforce. Incidents involving medical treatment
    rose by 41%, but recorded rates of lost time injury frequency and days
    lost frequency reduced by 8% and 74% respectively.
  oMinor increases in absolute measures across our environmental impacts, in
    part due to capacity expansion initiatives, however we achieved modest
    reductions in the amount of energy, greenhouse gas and water used to
    process each unit of plasma.
  oRelease of an updated edition of our Code of Responsible Business Practice
    in 15 languages.

About CSL Limited
Headquartered in Melbourne, Australia, CSL Limited (AUX:CSL) is a global
biopharmaceutical company that develops, manufactures and markets biotherapies
to prevent and treat rare and serious human diseases. CSL owns major
facilities in Australia, Germany, Switzerland and the US, and employs over
11,000 people in more than 25 countries. For more information visit
www.csl.com.au.

About CSL Behring
CSL Behring is a leader in the plasma protein therapeutics industry. Committed
to saving lives and improving the quality of life for people with rare and
serious diseases, the company manufactures and markets a range of
plasma-derived and recombinant therapies worldwide.

CSL Behring therapies are used around the world to treat coagulation disorders
including hemophilia and von Willebrand disease, primary immune deficiencies,
hereditary angioedema and inherited respiratory disease, and neurological
disorders in certain markets. The company's products are also used in cardiac
surgery, organ transplantation, burn treatment and to prevent hemolytic
diseases in the newborn.

CSL Behring operates one of the world's largest plasma collection networks,
CSL Plasma. CSL Behring is a global biopharmaceutical company and a member of
the CSL Group of companies. The parent company, CSL Limited (ASX:CSL), is
headquartered in Melbourne, Australia. For more information, visit
http://www.cslbehring.com/.

Contact:
Chris
Florentz
Manager Corporate Communications
CSL Behring
610-878-4316
Christopher.Florentz@cslbehring.com

SOURCE CSL Behring

Website: http://www.cslbehring.com